A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral ...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe ...

This research shows that an insect cells-baculovirus expression vector system can be used to create high-quality SARS-CoV-2 S protein for the implementation in a virosome-based COVID-19 vaccine ...

Pevion Biotech SA was the exclusive manufacturer for Mymetics' clinical stage HIV and malaria virosome vaccine candidates until they stopped operations. Consequently Mymetics has further secured ...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe ...

EPALINGES, SWITZERLAND--(Marketwired - Mar 10, 2014) - Mymetics (MYMX) announced today that it has secured and further strengthened its know-how and leadership in the research and development of ...

Pevion Biotech’s existing investors have put another CHF10 million (about $9.7 million) into the firm to help fund continued progression of its pipeline of virosome-based vaccine candidates.

MYMETICS Corporation Acquires Virosome Biologicals B.V. Mymetics Corporation (http://www.mymetics.com) (OTC BB:MYMX.OB - News) announced today that it has signed a ...

Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine ...